VRN101099 Phase 1 PK Study Evaluating Food and PPI Effects on Absorption
Summary
A Phase 1 pharmacokinetic clinical trial (NCT07550946) registered on ClinicalTrials.gov evaluates how food and a proton pump inhibitor affect the absorption of the investigational drug VRN101099 in healthy adult participants. The study will measure drug concentration in the bloodstream and urinary excretion patterns under three conditions: with food, with a PPI, and in a fasted state. Results are intended to inform future dosing recommendations for VRN101099 in treating solid tumors and cancers.
“Researchers will measure how much of the drug gets into the bloodstream and how fast it gets there in each situation.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This entry documents a Phase 1 clinical trial registration for VRN101099, an investigational drug under development for solid tumors and cancers. The study enrolls healthy adult participants to evaluate pharmacokinetic parameters under three conditions: fasted, with food, and with concomitant proton pump inhibitor administration. Researchers will assess maximum drug concentration in blood (Cmax), time to reach Cmax (Tmax), and urinary excretion rates.
Affected parties include pharmaceutical sponsors conducting early-phase oncology drug development and clinical research organizations conducting bioequivalence/food-effect studies. The data generated may inform future pivotal trial design and prescribing information for VRN101099. No compliance obligations are created by this registration entry itself.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN101099 in Healthy Adult Participants
Phase 1 NCT07550946 Kind: PHASE1 Apr 24, 2026
Abstract
This Clinical trial is being done to understand how food and a common stomach-acid reducing medicine (called a proton pump inhibitor-PPI) affect how the body absorbs a new drug, VRN101099, in healthy adults.
Researchers will measure how much of the drug gets into the bloodstream and how fast it gets there in each situation.
This will help identify the most effective way for future patients to use VRN101099 in the treatment of solid tumors and cancers.
The main questions it aims to answer is:
- Does food or a PPI change how the body absorbs a single dose of VRN101099?
- Is a single dose of VRN101099 safe and well tolerated when taken with or without food or a PPI?
- How is VRN101099 removed through urine when taken with or without food or a PPI?
Conditions: Healthy Adult
Interventions: VRN101099
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.